Type 2 diabetes mellitus (T2DM) has been identified as an extrahepatic manifestation of chronic HCV infection. Conversely, in the context of chronic HCV infection, T2DM can accelerate the course of HCV-induced liver disease leading to increased risk of fibrosis, cirrhosis and hepa-tocellular carcinoma. The presence of T2DM negatively impacts the efficacy of interferon-based antiviral therapy, but real-world data with high-efficacy direct-acting antiviral therapies suggest high viral clearance rates in T2DM patients. In HCV-infected individuals, viral eradication is associated with a reduced risk of de novo T2DM in non-diabetic patients and beneficial metabolic changes in patients with T2DM, highlighting the importance of antiviral treatment and physician awareness of this association.
References
1.
Polaris Observatory HCV Collaborators.Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.Lancet Gastroenterol Hepatol2017; 2: 161–176.
2.
GowerE., EstesC., BlachS., Razavi-ShearerK., RazaviH.Global epidemiology and genotype distribution of the hepatitis C virus infection.J Hepatol2014; 61: S45–S57.
3.
SebastianiG., GkouvatsosK., PantopoulosK.Chronic hepatitis C and liver fibrosis.World J Gastroenterol2014; 20: 11033–11053.
4.
CacoubP., GragnaniL., ComarmondC., ZignegoA.L.Extrahepatic manifestations of chronic hepatitis C virus infection.Dig Liver Dis2014; 46Suppl 2: S165–S173.
5.
DesboisA.C., CacoubP.Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review.World J Gastroenterol2017; 23: 1697–1711.
6.
ShiffmanM.L., GunnN.T.Impact of hepatitis C virus therapy on metabolism and public health.Liver Int2017; 37Suppl 2: 13–18.
7.
YounossiZ., ParkH., HenryL., AdeyemiA., StepanovaM.Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden.Gastroenterology2016; 150: 1599–1608.
8.
WhiteD.L., RatziuV., El-SeragH.B.Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.J Hepatol2008; 49: 831–844.
9.
AntonelliA., FerriC., FallahiP.Hepatitis C virus infection: evidence for an association with type 2 diabetes.Diabetes Care2005; 28: 2548–2550.
10.
KnoblerH., SchihmanterR., ZifroniA., FenakelG., SchattnerA.Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection.Mayo Clin Proc2000; 75: 355–359.
11.
MasonA.L., LauJ.Y., HoangN.Association of diabetes mellitus and chronic hepatitis C virus infection.Hepatology1999; 29: 328–333.
12.
ZeinN.N., AbdulkarimA.S., WiesnerR.H., EganK.S., PersingD.H.Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease.J Hepatol2000; 32: 209–217.
13.
HuiJ.M., SudA., FarrellG.C.Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression.Gastroenterology2003; 125: 1695–1704.
14.
GuoX., JinM., YangM., LiuK., LiJ.W.Type 2 diabetes mellitus and the risk of hepatitis C virus infection: a systematic review.Sci Rep2013; 3: 2981.
15.
LeandroG., MangiaA., HuiJ.Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.Gastroenterology2006; 130: 1636–1642.
16.
PettaS., CammaC., Di MarcoV.Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.Am J Gastroenterol2008; 103: 1136–1144.
17.
MiyaakiH., IchikawaT., TauraN.Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome.Intern Med2011; 50: 1137–1141.
18.
PersicoM., MasaroneM., La MuraV.Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities.World J Gastroenterol2009; 15: 462–466.
19.
LiX., GaoY., XuH., HouJ., GaoP.Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients.Sci Rep2017; 7: 9087.
20.
HuangY.W., YangS.S., FuS.C.Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: a nationwide cohort study.Hepatology2014; 60: 807–814.
21.
LiuT.L., TrogdonJ., WeinbergerM., FriedB., BarrittA.S.IVDiabetes is associated with clinical decompensation events in patients with cirrhosis.Dig Dis Sci2016; 61: 3335–3345.
22.
LiX., XuH., GaoY., PanM., WangL., GaoP.Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naive chronic hepatitis C patients in China.Medicine (Baltimore)2017; 96: e6508.
23.
HuangY.W., WangT.C., YangS.S.Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study.Aliment Pharmacol Ther2015; 42: 902–911.
24.
VeldtB.J., ChenW., HeathcoteE.J.Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus.Hepatology2008; 47: 1856–1862.
25.
RüegerS., BochudP.Y., DufourJ.F.Impact of common risk factors of fibrosis progression in chronic hepatitis C.Gut2015; 64: 1605–1615.
26.
ElkriefL., ChouinardP., BenderskyN.Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C.Hepatology2014; 60: 823–831.
27.
GreggE.W., LiY., WangJ.Changes in diabetes-related complications in the United States, 1990-2010.N Engl J Med2014; 370: 1514–1523.
28.
DzauV.J., AntmanE.M., BlackH.R.The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).Circulation2006; 114: 2850–2870.
29.
NegroF.Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases.J Hepatol2014; 61: S69–S78.
AytugS., ReichD., SapiroL.E., BernsteinD., BegumN.Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.Hepatology2003; 38: 1384–1392.
32.
LeratH., ImacheM.R., PolyteJ.Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice.J Biol Chem2017; 292: 12860–12873.
33.
VanniE., AbateM.L., GentilcoreE.Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C.Hepatology2009; 50: 697–706.
34.
MilnerK.L., van der PoortenD., TrenellM.Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance.Gastroenterology2010; 138: 932–941.e1-3.
35.
SabirS.N., ManzoorS., ParvaizF., SaalimM., GhaniE.Quantitative evaluation of insulin resistance markers in Pakistani patients suffering from HCV-associated type 2 diabetes mellitus.Acta Virol2017; 61: 197–203.
36.
VanniE., BugianesiE., SaraccoG.Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality?Dig Liver Dis2016; 48: 105–111.
37.
GreenbergA.S., McDanielM.L.Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes.Eur J Clin Invest2002; 32Suppl 2: 24–34.
38.
NaritaR., AbeS., KiharaY., AkiyamaT., TabaruA., OtsukiM.Insulin resistance and insulin secretion in chronic hepatitis C virus infection.J Hepatol2004; 41: 132–138.
39.
MasiniM., CampaniD., BoggiU.Hepatitis C virus infection and human pancreatic beta-cell dysfunction.Diabetes Care2005; 28: 940–941.
40.
American Diabetes Association.2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018.Diabetes Care2018; 41: S13–S27.
41.
HammerstadS.S., GrockS.F., LeeH.J., HashamA., SundaramN., TomerY.Diabetes and hepatitis C: a two-way association.Front Endocrinol (Lausanne)2015; 6: 134.
42.
European Association for the Study of the Liver (EASL).EASL recommendations on treatment of hepatitis C 2016.J Hepatol2017; 66: 153–194.
43.
AASLD and IDSA.HCV guidance: recommendations for testing, managing, and treating hepatitis C.2017. (Accessed 11 October 2017.) Available from http://www.hcvguidelines.org/.
44.
Ramos-CasalsM., ZignegoA.L., FerriC.Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.J Hepatol2017; 66: 1282–1299.
45.
ZignegoA.L., Ramos-CasalsM., FerriC.International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement.Autoimmun Rev2017; 16: 523–541.
46.
SinghS., SinghP.P., SinghA.G., MuradM.H., SanchezW.Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.Am J Gastroenterol2013; 108: 881–891.
47.
NkontchouG., CossonE., AoutM.Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients.J Clin Endocrinol Metab2011; 96: 2601–2608.
48.
LaiS.W., ChenP.C., LiaoK.F., MuoC.H., LinC.C., SungF.C.Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.Am J Gastroenterol2012; 107: 46–52.
49.
ZhangX., HarmsenW.S., MettlerT.A.Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.Hepatology2014; 60: 2008–2016.
50.
KimG., JangS.Y., HanE.Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: a nationwide nested case-control study.Int J Cancer2017; 140: 798–806.
51.
TsanY.T., LeeC.H., HoW.C., LinM.H., WangJ.D., ChenP.C.Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection.J Clin Oncol2013; 31: 1514–1521.
52.
DeltenreP., LouvetA., LemoineM.Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.J Hepatol2011; 55: 1187–1194.
53.
EslamM., AparceroR., KawaguchiT.Meta-analysis: insulin resistance and sustained virological response in hepatitis C.Aliment Pharmacol Ther2011; 34: 297–305.
54.
LauritoM.P., PariseE.R.Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis.Braz J Infect Dis2013; 17: 555–563.
55.
BackusL.I., BoothroydD.B., PhillipsB.R., MoleL.A.Predictors of response of US veterans to treatment for the hepatitis C virus.Hepatology2007; 46: 37–47.
56.
HungC.H., LeeC.M., WangJ.H.Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.Int J Cancer2011; 128: 2344–2352.
BackusL.I., BelperioP.S., ShahoumianT.A., LoomisT.P., MoleL.A.Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.Hepatology2016; 64: 405–414.
59.
FoxD.S., McGinnisJ.J., Tonnu-MiharaI.Q., McCombsJ.S.Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: data from the Veterans administration.J Gastroenterol Hepatol2017; 32: 1136–1142.
60.
Leventer-RobertsM., HammermanA., BrufmanI.Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: a population-based observational study.PLoS One2017; 12: e0176858.
61.
AghemoA., PratiG.M., RumiM.G.Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.Hepatology2012; 56: 1681–1687.
62.
ThompsonA.J., PatelK., ChuangW.L.Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.Gut2012; 61: 128–134.
63.
AdinolfL.E., NevolaR., GuerreraB.HCV clearance by direct-acting antiviral treatments reverses insulin resistance in chronic hepatitis C patients.J Gastroenterol Hepatol2017; 33: 1379–1382.
64.
Romero-GómezM., Fernandez-RodriguezC.M., AndradeR.J.Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.J Hepatol2008; 48: 721–727.
65.
AraseY., SuzukiF., SuzukiY.Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.Hepatology2009; 49: 739–744.
66.
PandyaP., PantC., TaylorR., OniO.Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome.J Investig Med2017; 65: 765–771.
67.
LiJ., ZhangT., GordonS.C.Impact of sustained virological response on incidence of type 2 diabetes in hepatitis C patients.Hepatology2017; 66: 531A.
68.
CacoubP., DesboisA.C., ComarmondC., SaadounD.Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.Gut2018; doi:10.1136/gutjnl-2018-316234.
69.
MeissnerE.G., LeeY.J., OsinusiA.Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.Hepatology2015; 61: 790–801.
70.
MoralesA.L., JungaZ., SinglaM.B., SjogrenM., TorresD.Hepatitis C eradication with sofosbuvir leads to significant metabolic changes.World J Hepatol2016; 8: 1557–1563.
71.
MehtaD.A., CohenE., CharafeddineM.Effect of hepatitis C treatment with ombitasvir/paritaprevir/R + dasabuvir on renal, cardiovascular and metabolic extrahepatic manifestations: a post-hoc analysis of Phase 3 clinical trials.Infect Dis Ther2017; 6: 515–529.
72.
PavoneP., TieghiT., d'EttorreG.Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents.Clin Microbiol Infect2016; 22: 462.e1–462.e3.
73.
Abdel AlemS., ElsharkawyA., FouadR.Improvement of glycemic state among responders to sofosbuvir-based treatment regimens: single center experience.J Med Virol2017; 89: 2181–2187.
74.
DawoodA.A., NoohM.Z., ElgamalA.A.Factors associated with improved glycemic control by direct-acting antiviral agent treatment in Egyptian type 2 diabetes mellitus patients with chronic hepatitis C genotype 4.Diabetes Metab J2017; 41: 316–321.
75.
CiancioA., BosioR., BoS.Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents.J Med Virol2018; 90: 320–327.
76.
HumJ., JouJ.H., GreenP.K.Improvement in glycemic control of type 2 diabetes after successful treatment of hepatitis C virus.Diabetes Care2017; 40: 1173–1180.
77.
HsuY.C., HoH.J., HuangY.T.Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection.Gut2015; 64: 495–503.
78.
HsuC.S., KaoJ.H., ChaoY.C.Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.Aliment Pharmacol Ther2013; 38: 415–423.
79.
AraseY., SuzukiF., KawamuraY.Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy.Hepatol Res2011; 41: 946–954.
80.
AraseY., KobayashiM., KawamuraY.Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.J Med Virol2014; 86: 169–175.
81.
HsuY.C., LinJ.T., HoH.J.Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.Hepatology2014; 59: 1293–1302.
82.
BrunoS., StroffoliniT., ColomboM.Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.Hepatology2007; 45: 579–587.
83.
van der MeerA.J., VeldtB.J., FeldJ.J.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.JAMA2012; 308: 2584–2593.
84.
van der MeerA.J., FeldJ.J., HoferH.Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.J Hepatol2017; 66: 485–493.
85.
IoannouG.N., GreenP.K., BerryK.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.J Hepatol2018; 68: 25–32.
86.
CalvarusoV., CabibboG., CacciolaI.Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents.Gastroenterology2018; 155: 411–421.
